搜尋結果
BioNTech和辉瑞将携手合作，扩大产能以应对此次疫情。. BioNTech和辉瑞还将在监管部门批准后共同努力，在全球范围内将这种疫苗商业化（中国除外，因为BioNTech与复星医药的合作已涵盖了中国）。. 辉瑞首席科学家兼全球研发及医学总裁Mikael Dolsten指出：“抗击 ...
2023年9月11日 · The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) includes a monovalent (single) component that corresponds to the Omicron variant XBB.1.5 of SARS-CoV-2. The Pfizer-BioNTech COVID-19 ...
2022年8月23日 · today announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine efficacy data ...
2022年7月8日 · Pfizer and BioNTech have also submitted a sBLA to the U.S. FDA to extend the approval of COMIRNATY to include booster doses for individuals ages 16 years and older, who are currently authorized under EUA. COMIRNATY, which is based on BioNTech’s
2020年11月18日 · Pfizer and BioNTech plan to submit the efficacy and safety data from the study for peer-review in a scientific journal once analysis of the data is completed. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global ...
The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other ...
2023年10月26日 · This release contains forward-looking information about Pfizer’s and BioNTech’s mRNA-based combination vaccine candidate for influenza and COVID-19 among healthy adults 18 to 64 years of age, including its potential benefits, plans to initiate a pivotal Phase
